GAYNOR RICHARD — SEC insider filings
SEC reporting owner CIK 1741284. 26 insider filings on record with FilingPulse; latest filed 2026-11-13.
Transaction summary — filings shown
Covers all 26 filings on record, filed 2020-12-04 to 2026-11-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 3 filings — 4,695 shares, $99,193 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 5,000 shares, $136,425 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 52.
- Largest priced transaction: sale of 2,500 shares @ $35.07 ($87,675) in Zai Lab Ltd, filed 2025-03-06.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Zai Lab Ltd (ZLAB) | Director | 10 | 3 legs · 4,695 sh · $99,193 | 2 legs · 5,000 sh · $136,425 | 5 |
| Alkermes plc. (ALKS) | Director | 14 | — | — | 45 |
| INFINITY PHARMACEUTICALS, INC. (INFI) | Director | 2 | — | — | 2 |
Insider filings — GAYNOR RICHARD
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-13 | 4 | Zai Lab Ltd (ZLAB) | Purchase (P): 1,228 @ $27.19 | EDGAR |
| 2026-07-06 | 4 | Zai Lab Ltd (ZLAB) | Purchase (P): 1,736 @ $19.05 | EDGAR |
| 2026-06-22 | 4 | Zai Lab Ltd (ZLAB) | Grant/award (A): 22,371 @ $0 | EDGAR |
| 2026-05-22 | 4/A | Alkermes plc. (ALKS) | Grant/award (A): 11,538 (derivative) @ $0 · Grant/award (A): 5,409 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Alkermes plc. (ALKS) | Option exercise (M): 6,142 · Tax withholding (F): 1,475 @ $36.95 · Grant/award (A): 11,538 (derivative) @ $0 · Grant/award (A): 5,409 (derivative) @ $0 · Option exercise (M): 6,142 (derivative) | EDGAR |
| 2026-03-19 | 4 | Zai Lab Ltd (ZLAB) | Purchase (P): 1,731 @ $18.91 | EDGAR |
| 2025-06-23 | 4 | Zai Lab Ltd (ZLAB) | Grant/award (A): 10,831 @ $0 | EDGAR |
| 2025-06-02 | 4 | Alkermes plc. (ALKS) | Option exercise (M): 8,013 · Tax withholding (F): 1,924 @ $30.61 · Option exercise (M): 8,013 (derivative) | EDGAR |
| 2025-05-23 | 4 | Alkermes plc. (ALKS) | Grant/award (A): 13,474 (derivative) @ $0 · Grant/award (A): 6,142 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | Zai Lab Ltd (ZLAB) | Sale (S): 2,500 @ $35.07 | EDGAR |
| 2024-09-05 | 4 | Zai Lab Ltd (ZLAB) | Sale (S): 2,500 @ $19.50 | EDGAR |
| 2024-07-01 | 4 | Alkermes plc. (ALKS) | Option exercise (M): 6,104 · Tax withholding (F): 1,465 @ $24.10 · Option exercise (M): 6,104 (derivative) | EDGAR |
| 2024-06-20 | 4 | Zai Lab Ltd (ZLAB) | Grant/award (A): 21,253 @ $0 | EDGAR |
| 2024-06-04 | 4 | Alkermes plc. (ALKS) | Other (J): 1,236 (derivative) @ $20.81 · Other (J): 224 (derivative) @ $20.81 · Other (J): 256 (derivative) @ $16.52 · Other (J): 230 (derivative) @ $18.45 · Other (J): 313 (derivative) @ $24.24 · Other (J): 231 (derivative) @ $30.86 · +4 more | EDGAR |
| 2023-07-10 | 4 | Alkermes plc. (ALKS) | Option exercise (M): 5,957 · Tax withholding (F): 1,430 @ $29.88 · Option exercise (M): 5,957 (derivative) | EDGAR |
| 2023-06-30 | 4 | Alkermes plc. (ALKS) | Grant/award (A): 12,732 (derivative) @ $0 · Grant/award (A): 5,985 (derivative) @ $0 | EDGAR |
| 2023-06-30 | 4 | Zai Lab Ltd (ZLAB) | Grant/award (A): 18,903 @ $26.45 | EDGAR |
| 2022-07-08 | 4 | Alkermes plc. (ALKS) | Grant/award (A): 5,957 (derivative) @ $0 · Grant/award (A): 11,554 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | INFINITY PHARMACEUTICALS, INC. (INFI) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | Alkermes plc. (ALKS) | Option exercise (M): 7,585 · Tax withholding (F): 695 @ $27.19 · Option exercise (M): 7,585 (derivative) | EDGAR |
| 2021-12-03 | 4 | Alkermes plc. (ALKS) | Option exercise (M): 5,578 · Tax withholding (F): 1,339 @ $22.11 · Option exercise (M): 5,578 (derivative) | EDGAR |
| 2021-11-22 | 4 | Zai Lab Ltd (ZLAB) | Grant/award (A): 8,912 @ $0 | EDGAR |
| 2021-06-16 | 4 | Alkermes plc. (ALKS) | Grant/award (A): 15,677 (derivative) @ $0 · Grant/award (A): 7,585 (derivative) @ $0 | EDGAR |
| 2021-06-11 | 4 | INFINITY PHARMACEUTICALS, INC. (INFI) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2021-05-21 | 4 | Alkermes plc. (ALKS) | Option exercise (M): 6,104 @ $0 · Tax withholding (F): 1,404 @ $21.92 · Option exercise (M): 6,104 (derivative) @ $0 | EDGAR |
| 2020-12-04 | 4 | Alkermes plc. (ALKS) | Grant/award (A): 11,509 (derivative) @ $0 · Grant/award (A): 5,578 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1741284 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs